{"id":1524,"date":"2010-10-01T12:07:00","date_gmt":"2010-10-01T10:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/leserbrief-17"},"modified":"2010-10-01T12:07:00","modified_gmt":"2010-10-01T10:07:00","slug":"leserbrief-17","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2010\/leserbrief-17","title":{"rendered":"Leserbrief"},"content":{"rendered":"<p>Leserbrief Therapie der Multiplen Sklerose Prof. Dr. H.-P. V. aus Berlin schreibt: >> Im Juni-Heft des ARZNEIMITTELBRIEFS wurde die Rezidivprophylaxe der MS mit Cladribin (Leustatin\u00ae, Litak\u00ae) und Fingolimod (FTY720) besprochen (1). Es wundert mich, dass weder in der Originalliteratur, noch in Ihrem Kommentar der Vergleich mit Azathioprin er\u00f6rtert wird. Azathioprin ist auch wirksam (2), und [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Leserbrief Therapie der Multiplen Sklerose Prof. Dr. H.-P. V. aus Berlin schreibt: >> Im Juni-Heft des ARZNEIMITTELBRIEFS wurde die Rezidivprophylaxe der MS mit Cladribin (Leustatin\u00ae, Litak\u00ae) und Fingolimod (FTY720) besprochen (1). Es wundert mich, dass weder in der Originalliteratur, noch in Ihrem Kommentar der Vergleich mit Azathioprin er\u00f6rtert wird. Azathioprin ist auch wirksam (2), und [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[189,239,188,1007,352],"class_list":["post-1524","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-2-chlordesoxyadenosin","tag-azathioprin","tag-cladribin","tag-fingolimod","tag-multiple-sklerose"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1524","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1524"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1524\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1524"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1524"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}